Naslov
FLT3 internal tandem duplication is a poor risk factor in patients with AML with diverse cytogenetic features

Autori
Mikulic, Mirta ; Zadro, Renata ; Davidovic, Sanja ; Serventi Seiwerth, Ranka ; Sertic, Dubravka ; Nemet, Damir ; Batinic, Josip ; Batinic, Drago ; Gjadrov, Koraljka ; Ries, Sunčica ; Labar, Boris

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Leukemia and Lymphoma East and West Are Together - Knjiga sažetaka / Arić, Branimir - Zagreb : Hrvatski liječnički zbor, 2011, 90-90

Skup
2nd Leukemia and Lymphoma Meeting – East and West Are Together

Mjesto i datum
Dubrovnik, Hrvatska, 17.09.2011. - 21.09.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
FLT3 ; risk factors ; AML

Sažetak
Aim: Mutations of Fms-like tyrosine kinase 3 (FLT3) are present in about 30% of acute myelogenous leukemia (AML) patients that have been shown to have poor prognosis. The aim of this study was to analyze the prognostic impact of FLT3 internal tandem duplication (ITD) on the outcome of patients diagnosed with AML in comparison with patients with wild-type (WT) FLT3. Patients and methods: We retrospectively analyzed the laboratory and clinical data in 78 newly diagnosed patients with AML who have been treated in our Center from 02/2000-03/2010. Median patients’ age was 45 years (range, 22–72 yrs.). AML diagnosis was based on morphological, immunophenotypical and cytogenetical features. The presence of FLT3 ITD was detected by RT-PCR analysis. All patients received intensive induction chemotherapy followed by consolidation chemotherapy ; 36 patients were treated with autologous hematopoietic stem cell transplantation (SCT) in 1st CR, while 8 and 3 patients were allografted in 1st and >1st CR, respectively. Results: FLT3-ITD was detected in 20 patients (25%). Eight FLT3-ITD patients had normal karyotypes, two had good, and two had intermediate cytogenetic features. Thirteen FLT3-WT patients had normal karyotypes, five had good, nine had poor, and nine had intermediate cytogenetic features. In 30 patients from both groups cytogenetic studies had failed. CR rate was 85% in FLT3-ITD patients and 71% in FLT3-WT patients (p=0.249). 2-year DFS was 33.8 and 52.5% in the FLT3-ITD and FLT3-WT group, respectively (p=0.029). 2- year OS was 47.3 and 63% in the FLT3- ITD and FLT3-WT group, respectively (p=0.665). Conclusion: A higher remission rate after induction, although not statistically significant, was found in the FLT3- ITD group. Contrary to that, the DFS was significantly better in patients with FLT3-WT and a trend for better OS was observed in patients with FLT3- WT. This data support the evidence for FLT3-ITD being a poor risk factor, not only in patients with normal karyotypes, but also in patients with different cytogenetic risk factors.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA